Marshall Wace North America L.P. purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 757,154 shares of the medical research company’s stock, valued at approximately $74,201,000.
A number of other hedge funds also recently modified their holdings of DGX. Norges Bank bought a new stake in shares of Quest Diagnostics during the fourth quarter worth $150,523,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of Quest Diagnostics during the first quarter worth $74,201,000. Janus Capital Management LLC increased its stake in shares of Quest Diagnostics by 86.0% in the fourth quarter. Janus Capital Management LLC now owns 997,531 shares of the medical research company’s stock worth $91,674,000 after buying an additional 461,187 shares during the period. Seizert Capital Partners LLC bought a new stake in shares of Quest Diagnostics during the first quarter worth $31,483,000. Finally, AMF Pensionsforsakring AB bought a new stake in shares of Quest Diagnostics during the fourth quarter worth $27,753,000. 90.71% of the stock is owned by hedge funds and other institutional investors.
Quest Diagnostics Incorporated (DGX) traded up 0.33% during trading on Tuesday, hitting $108.50. 299,762 shares of the stock were exchanged. Quest Diagnostics Incorporated has a 52 week low of $77.29 and a 52 week high of $110.28. The stock has a market capitalization of $14.85 billion, a price-to-earnings ratio of 21.84 and a beta of 0.72. The firm has a 50-day moving average of $107.54 and a 200-day moving average of $98.57.
Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, April 20th. The medical research company reported $1.33 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.15. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Quest Diagnostics had a net margin of 9.34% and a return on equity of 15.22%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.12 earnings per share. Equities research analysts anticipate that Quest Diagnostics Incorporated will post $5.57 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, July 24th. Stockholders of record on Monday, July 10th will be issued a $0.45 dividend. The ex-dividend date of this dividend is Thursday, July 6th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.66%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.29%.
COPYRIGHT VIOLATION WARNING: “Marshall Wace North America L.P. Invests $74.20 Million in Quest Diagnostics Incorporated (DGX)” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2655885/marshall-wace-north-america-l-p-invests-74-20-million-in-quest-diagnostics-incorporated-dgx.html.
DGX has been the subject of a number of research reports. Goldman Sachs Group, Inc. (The) raised shares of Quest Diagnostics from a “buy” rating to a “conviction-buy” rating and set a $113.00 price target for the company in a report on Tuesday, March 14th. Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a report on Wednesday, March 29th. Mizuho reissued a “buy” rating and issued a $90.00 price target (down from $103.00) on shares of Quest Diagnostics in a report on Friday, April 14th. Jefferies Group LLC reissued a “hold” rating and issued a $96.00 price target on shares of Quest Diagnostics in a report on Thursday, March 16th. Finally, Canaccord Genuity increased their price target on shares of Quest Diagnostics from $102.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, April 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $108.81.
In other news, SVP Michael E. Prevoznik sold 29,513 shares of the stock in a transaction dated Thursday, April 20th. The shares were sold at an average price of $100.00, for a total value of $2,951,300.00. Following the completion of the transaction, the senior vice president now owns 41,335 shares of the company’s stock, valued at $4,133,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jenne K. Britell sold 6,111 shares of the stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $104.03, for a total transaction of $635,727.33. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.